Sanctuary Advisors LLC Acquires 32,183 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Sanctuary Advisors LLC raised its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 82.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 71,444 shares of the biotechnology company’s stock after buying an additional 32,183 shares during the period. Sanctuary Advisors LLC’s holdings in Exelixis were worth $2,353,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of EXEL. Principal Securities Inc. increased its holdings in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Exelixis by 84.3% in the fourth quarter. Blue Trust Inc. now owns 11,231 shares of the biotechnology company’s stock worth $374,000 after purchasing an additional 5,137 shares during the last quarter. Klingenstein Fields & Co. LP bought a new stake in shares of Exelixis in the fourth quarter worth about $233,000. V Square Quantitative Management LLC increased its holdings in shares of Exelixis by 37.3% in the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 425 shares during the last quarter. Finally, Van ECK Associates Corp increased its holdings in shares of Exelixis by 45.4% in the fourth quarter. Van ECK Associates Corp now owns 252,324 shares of the biotechnology company’s stock worth $8,402,000 after purchasing an additional 78,740 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on EXEL shares. Wells Fargo & Company lifted their target price on Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. UBS Group lifted their target price on Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a report on Wednesday, October 30th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. Finally, Truist Financial lifted their price target on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Insider Activity at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. The trade was a 10.99 % decrease in their position. The disclosure for this sale can be found here. 2.85% of the stock is owned by company insiders.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $36.85 on Friday. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $37.59. The business has a 50 day simple moving average of $34.20 and a two-hundred day simple moving average of $31.28. The firm has a market capitalization of $10.31 billion, a PE ratio of 20.82, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.